Ra Medical Systems Inc (RMED)

[subslover]

After hours $4.71 up 91%

[TheFinalCD]

2.82 dip from 3.47

looks inviting

[subslover]

Catheter Precision’s VIVO™ System Used in More Than 800 Procedures in Leading U.S. and European Hospitals
December 01 2022 - 06:50AM
Business Wire
Alert
Print
Share On Facebook
Catheter Precision, Inc., a medical device and technology company focused on cardiac electrophysiology, announces that more than 800 procedures have been performed in a number of leading U.S. and European hospitals utilizing the VIVO System that enables physicians to noninvasively identify an area of ventricular arrhythmia onset. On September 12, 2022 privately held Catheter Precision announced a definitive merger agreement with Ra Medical Systems (NYSE American: RMED), which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market.

“We are always looking to the next milestone in clinical usage of our VIVO System and reaching 800 procedures by the end of 2022 was a goal we set earlier this year,” said David Jenkins, Catheter Precision CEO. “We are gratified by physician adoption so far through our strategic limited launch and look forward to expanding usage in 2023 by growing our sales and clinical support teams to access additional hospitals in new and existing territories. By expanding our footprint, we are bringing a valuable tool to electrophysiologists to help them gain a better understanding of patient anatomy and potentially improve outcomes while providing beneficial healthcare to more patients.”

Catheter Precision’s lead product, VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has been awarded the CE mark. The company also intends to pursue a second generation of Amigo®, a previously FDA-cleared and CE mark robotic arm that can be used to remotely control catheters outside of the procedure room. Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.

Under the terms of the definitive merger agreement with Ra Medical Systems, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in a stock-for-stock reverse merger transaction. The merger is expected to close in the fourth quarter of 2022 or the first quarter of 2023, subject to satisfying certain closing conditions, including the receipt of required shareholder approval.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

VIVO Indications for Use

VIVO is intended for acquisition, analysis, display and storage of cardiac electrophysiological data and maps for analysis by a physician.

VIVO is intended to be used as a pre-procedure planning tool for patients with structurally normal hearts undergoing ablation treatment for idiopathic ventricular arrhythmias.

Additional Information and Where to Find It

On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the “Merger Agreement”) with privately held Catheter Precision, Inc. (“Catheter”), a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the “Merger”). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices.

The Merger is currently expected to close before the end of 2022 or during the first

[TheFinalCD]

https://finance.yahoo.com/news/ra-medical-systems-raises-7-200500180.html

[Tom turtles]

No....wait...

[BarbaraWalters]

PT is $49 from here. This area is the bottom

[Jaydixson1]

Re load

[BoilerRoom]

Wow Mr. Morris dumping on folks?

[bowlfan912]

Nice little chunk of profit there.

[BoilerRoom]

I’m out too much selling

[BoilerRoom]

$RMED back in at $4.40

[subslover]

Ra Medical Systems Raises $7.6 Million Through Completed At-The-Market Facility
October 17 2022 - 04:05PM
Business Wire
Alert
Print
Share On Facebook
Ra Medical Systems, Inc. (NYSE American: RMED) (“Ra Medical” or the “Company”) announces the completion of its at-the-market (ATM) facility, raising gross proceeds of $7.6 million. The Company sold 1,072,246 shares of common stock at a weighted average price of $7.09 per share, as adjusted for a reverse split effected September 30, 2022, resulting in net proceeds of approximately $7.4 million after deducting sales commissions.

As of October 10, 2022, the Company had 2,161,429 shares of common stock outstanding. Ladenburg Thalmann & Co. Inc. served as the sales agent for the ATM.

“Proceeds from this offering help us meet the conditions of the proposed merger with Catheter Precision, and are another step toward bringing our shareholders the value of their groundbreaking electrophysiology technology to improve the treatment of cardiac arrhythmias,” said Will McGuire, Ra Medical CEO. “We are currently evaluating the next step in our plan to raise sufficient funds to satisfy the net cash merger condition and other liquidity needs, and we plan to file a definitive proxy for a Special Meeting of Stockholders to vote on the proposed merger as soon as we have cleared the Securities and Exchange Commission (“SEC”) comment process. Assuming the merger proposal passes in the anticipated timeframe and the other conditions under the merger agreement are satisfied, we continue to expect the transaction will be completed by the end of 2022.”

The shares in the ATM offering were sold pursuant to a shelf registration statement declared effective by the SEC on February 3, 2021 and a prospectus supplement filed with the SEC on September 2, 2022.

About Ra Medical Systems

Ra Medical Systems, Inc. is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System, is used as a tool in the treatment of peripheral artery disease.

Proposed Merger Agreement

On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the “Merger Agreement”) with privately held Catheter Precision, Inc., a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter Precision will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the “Merger”). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices.

Catheter Precision has three product areas that it intends to pursue. Its lead product, named VIVO™ (an acronym for View Into Ventricular Onset), is an FDA-cleared and CE mark product that utilizes non-invasive inputs to locate the origin of ventricular arrhythmias, and, through its use, the physician can identify patients for invasive catheter ablation, and with those patients, reduce the amount of time in the invasive procedure. Ventricular arrhythmias include ventricular

[subslover]

I like it as well, :)

[BoilerRoom]

$RMED haha I was right. Weeeeeeeeeee!

[BoilerRoom]

$RMED I like this one

[subslover]

Nothing surprises me with this market lol

[TheFinalCD]

RMED 6.60 getting interest again post reverse split

1 for 50 RS= https://finance.yahoo.com/news/ra-medical-systems-announces-results-204800803.html


https://finance.yahoo.com/news/ra-medical-systems-enters-agreements-123000824.html


On September 12, 2022, Ra Medical announced entering into an Agreement and Plan of Merger (the “Merger Agreement”) with privately held Catheter Precision, Inc. (“Catheter”), a medical device and technology company focused in the field of cardiac electrophysiology. Under the terms of the Merger Agreement, Catheter will become a wholly owned subsidiary of Ra Medical in a stock-for-stock reverse merger transaction (the “Merger”). If completed, the Merger will result in a combined publicly traded company that will focus on the cardiac electrophysiology market, one of the most robust and growing areas of medical devices.

[Golden Cross]

A lot of shares traded for only a 1 mil float....hmmm

[1Bigmac]

$$ RMED $$$: https://finance.yahoo.com/news/catheter-precision-vivo-technology-featured-120000772.html

[Invest-in-America]

RMED: And AGAIN!!! With a 1-for-50 REVERSE SPLIT announced!!! And it sends the stock SOARING????????? WHAT????? Likely their next PR will divulge that they are being INVESTIGATED for FRAUD!!! And THAT too will send its price SOARING!!!!

[tw0122]

Running nicely premarket in yesterday as they doing reverse split and reverse merger. Up to .17 yesterday was in .13s

[Invest-in-America]

RMED: And here we go AGAIN!! Get investigated, or get sued, & your stock price SOARS!!!

[kzivann]

Bid 15's ..Down down and down. R/S, merger ?

RMED

[MNK3240]

One day there will be a big spike and those aren’t taking a position now, will regret big time.

Remember, often if you take a position on a stock trading at or below 52 weeks low without major issues is a money maker, just a matter of time. DYDD

[StocktonCA]

Looks like Naked Shorts are hard at work keeping this from organically moving up so they can cover lower. this will move up once these invisible shares are off the imaginary books.

[Pt3]

Ok thank

[StocktonCA]

the AI Platforms help lesson the damages to shorts. this should continue upwards once the shorts have covered. this was trading much higher and now that FDA has approved their device..should go back up...remember we are in a bear market though...

[Pt3]

Where the squeeze now I'm trapped lol

[THEMASTERS_SON]

,,,,,,KEEP POUNDING $RMED TO 77c

[THEMASTERS_SON]

,,,,,,,WHY ARE THEY—PLAYING GAMES……SHOULD BE $1+

[THEMASTERS_SON]

,,,,,,,THE SQUEEEEEEEEEEZE IS REAL

[subslover]

On June 6, 2022, Ra Medical Systems, Inc. (the “Company”) initiated a reduction in force (the “Reduction”), in which approximately 65% of the Company’s full-time employees were immediately terminated, effective June 6, 2022, which is the date on which the Company notified such employees of their termination. As part of the Reduction, non-terminated employees have been offered conditional retention arrangements with the Company pursuant to which it is expected that they will continue to provide services during the immediate future for a period of approximately the next 60 days in exchange for a retention payment should the full term of service be completed, during which time the Company and its Board of Directors (the “Board”) will continue to actively evaluate and monitor the Company’s near-term personnel needs based in part on the Company’s financial status and the Board’s review of strategic alternatives. The purpose of the Reduction, which was approved by the Board on June 3, 2022, is to preserve capital with the goal of maximizing the opportunities available to the Company during the Board’s review of strategic alternatives.



The total costs related to the Reduction are estimated to be approximately $1 million in future cash outlays primarily related to severance and retention costs as well as related expenses, which the Company expects to record in the second and third quarters of 2022.



The Company may incur additional expenses not currently contemplated due to events associated with the Reduction. The changes that the Company expects to incur in connection with the Reduction are estimates and subject to a number of assumptions, and actual results may differ materially.

[Flicker1]

https://fda.report/PMN/K220544

[heyitsmeagain]

Added more here looking for higher

[heyitsmeagain]

Loaded boom

[heyitsmeagain]

Gonna boom back high

[knrorrel]

LOOKS NOW BOOOM AGAIN

[TheFinalCD]

whats the boom for?

did I miss something

[knrorrel]

BOOOOOOOOOOOOM https://www.nasdaq.com/market-activity/stocks/rmed/real-time

[MASTERULTRA]

Market Cap shows $2.8 million but they have $16million doesnt that mean its worth $5/ per shares at minimum?

[mik1234]

it is funny yahoo finance say rmed 1y Target Est 12.00 it will not touch 1.

[mik1234]

oops becarful red rmed .0001!

[TheFinalCD]

$44M dollars traded its amazing when the algos get triggered

[BooDog]

Another nice pop today. This was just a quick swing for me. Especially these days!

Cheers!

[TheFinalCD]

$RMED You can have her heart I just want the ass

— Zack Morris (@MrZackMorris) March 1, 2022

[BooDog]

Short lived pinch. But it was still a pinch.


Cheers!

[georgie18]

Thank you...Best to you as well...

[BooDog]

I figured as much. We'll see if this turns into anything more than a technical play.

Best of luck!!

Started building here .4085.

[georgie18]

I been out for a bit...thanks...

[BooDog]

Possible pinch setting up. May be worth the gamble. Haven't looked at this since last October. Time flies!!

RMED daily

Another raise paying out @ .50. More dilution. That's the definition of bio startups. But still, some manage much better than this one imo.

See how it goes.

$RMED .41.